Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuing Treatment with Dasatinib
NCT02297139Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2015
- Primary completion
- May 2022
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 2
01
Overview
A Phase 2 trial of dasatinib in cancer, sponsored by Bristol Myers Squibb. Started Jul 2015; status: completed.
02
Drugs
dasatinib
03
Conditions
cancer
Beyond the preview
Go deeper on NCT02297139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02297139.